In COVID-19, serum IL-6 is considered to be a physiologically relevant biomarker associated with disease progression, and it has been proposed that IL-6 receptor blocking medicine could aid in the therapeutic improvement in individuals with severe and critical COVID-19 [32]. This evidence concerns the gene IL6 and COVID-19.